Recent investigations have demonstrated that MYCN-high cancer cells exhibit heightened ferroptosis sensitivity compared with their MYCN-low counterparts, paving the way for the development of a targeted ferroptosis-inducing therapy for effectively treating MYCN-high neuroblastomas (Alborzinia et al., 2022). The gene discussed is MYCN; the disease is cancer.